Day One Biopharms Drug Patent Portfolio
Day One Biopharms owns 1 orange book drug protected by 2 US patents Given below is the list of Day One Biopharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10426782 | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation | 23 Jun, 2035 | Active |
| US8293752 | Compounds useful as Raf kinase inhibitors | 04 Aug, 2031 | Active |
Latest Legal Activities on Day One Biopharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Day One Biopharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 19 Aug, 2025 | US8293752 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US8293752 |
| Letter from FDA or Dept of Agriculture re PTE application | 27 Jun, 2025 | US8293752 |
| Information Disclosure Statement (IDS) Filed | 27 Jun, 2025 | US8293752 |
| Electronic Review | 30 Jul, 2024 | US8293752 |
| Initial letter Re: PTE Application to regulating agency | 29 Jul, 2024 | US8293752 |
| Patent Term Extension Application under 35 USC 156 Filed | 18 Jun, 2024 | US8293752 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Mar, 2024 | US8293752 |
|
Email Notification
Critical
| 15 Nov, 2023 | US8293752 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 Nov, 2023 | US8293752 |
| Mail Pre-Exam Notice | 01 Jun, 2023 | US8293752 |
|
Email Notification
Critical
| 01 Jun, 2023 | US8293752 |
|
Electronic Review
Critical
| 01 Jun, 2023 | US8293752 |
|
Electronic Review
Critical
| 22 May, 2023 | US8293752 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 22 May, 2023 | US8293752 |
Day One Biopharms's Family Patents
Day One Biopharms Drug List
Given below is the complete list of Day One Biopharms's drugs and the patents protecting them.
1. Ojemda
Ojemda is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10426782 | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation |
23 Jun, 2035
(9 years from now)
| Active |
| US8293752 | Compounds useful as Raf kinase inhibitors |
04 Aug, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ojemda's drug page